Cordlife Group Limited (SGX:P8A)

Market Cap	33.32M -11.6%
Revenue (ttm)	38.85M +40.5%
Net Income	-12.64M
EPS	-0.05
Shares Out	256.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,600
Average Volume	25,345
Open	0.1300
Previous Close	0.1240
Day's Range	0.1300 - 0.1310
52-Week Range	0.1210 - 0.3300
Beta	0.68
RSI	42.91
Earnings Date	Feb 26, 2026

About Cordlife Group

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test ...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 538
• Stock Exchange: Singapore Exchange
• Ticker Symbol: P8A

Financial Performance

In 2025, Cordlife Group's revenue was 38.85 million, an increase of 40.53% compared to the previous year's 27.65 million. Losses were -12.64 million, -33.06% less than in 2024.